Trial Profile

A German, non-Interventional study of NEPA (fixed dose Netupitant/Palonosetron) for the prevention of chemotherapy induced nausea and vomiting

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Jan 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Netupitant/palonosetron (Primary)
Indications Chemotherapy-induced nausea and vomiting
Focus Therapeutic Use
Acronyms AkyPRO

Most Recent Events

11 Dec 2020 Results of post-hoc analysis assessing quality of life data and effectiveness of NEPA in the subgroup of Breast Cancer patients in two age groups > and <60 years, presented at the 43rd Annual San Antonio Breast Cancer Symposium.
08 Dec 2020 Status changed from active, no longer recruiting to completed.
08 Dec 2020 Results of quality of life presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com